Literature DB >> 16497473

Surgery for thyroid Hürthle cell tumours--a single institution experience.

I Paunovic1, K Krgovic, S Tatic, A Diklic, V Zivaljevic, N Kalezic, M Havelka.   

Abstract

AIMS: The objective of the study was to report a series of patients with Hürthle cell tumours.
METHODS: We reviewed medical records of single institution from January 1982 to December 2002, including follow-up information.
RESULTS: We identified 199 patients with Hürthle cell tumours (HCT), 88 patients with Hürthle cell carcinoma (HCC) and 111 patients with Hürthle cell adenoma (HCA). The HCC group had significantly longer duration of the disease and larger tumours (4.8 vs 3.8 cm) compared with HCA group. Gender appeared to play significant role in patients with HCT (women outnumbered man by 7:1; p < 0.01). Surgical management for 80% of patients with HCA consisted of hemithyroidectomy and total thyroidectomy in 87% patients in the HCC group. Temporary laryngeal nerve palsy and temporary hypoparathyroidismus were not seen in HCA group, in HCC group were confirmed in 2.27 and 3.41%, respectively. Four patients with HCC relapsed and two died of HCC.
CONCLUSIONS: HCC has outlook for favorable outcome when treated radically with total thyroidectomy.

Entities:  

Mesh:

Year:  2006        PMID: 16497473     DOI: 10.1016/j.ejso.2005.11.023

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

Review 1.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

2.  Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.

Authors:  Yi Wei Zhang; David Yu Greenblatt; Daniel Repplinger; Anna Bargren; Joel T Adler; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-07-30       Impact factor: 5.344

3.  Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid.

Authors:  Rebecca S Sippel; Dina M Elaraj; Elham Khanafshar; Rasa Zarnegar; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

4.  Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes.

Authors:  Adolfo Pisanu; Barbara Di Chiara; Isabella Reccia; Alessandro Uccheddu
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

5.  Prognostic factors for disease-specific survival in 108 patients with Hürthle cell thyroid carcinoma: a single-institution experience.

Authors:  Rok Petric; Barbara Gazic; Nikola Besic
Journal:  BMC Cancer       Date:  2014-10-23       Impact factor: 4.430

6.  Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience.

Authors:  Nikola Besic; Andreja Schwarzbartl-Pevec; Barbara Vidergar-Kralj; Tea Crnic; Barbara Gazic; Maja Marolt Music
Journal:  BMC Cancer       Date:  2016-02-26       Impact factor: 4.430

7.  Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience.

Authors:  Branisav Oluic; Ivan Paunovic; Zlatibor Loncar; Vladimir Djukic; Aleksandar Diklic; Milan Jovanovic; Zeljko Garabinovic; Nikola Slijepcevic; Branislav Rovcanin; Dusan Micic; Aleksandar Filipovic; Vladan Zivaljevic
Journal:  BMC Cancer       Date:  2017-05-25       Impact factor: 4.430

8.  Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms.

Authors:  Andrej Vogrin; Hana Besic; Nikola Besic; Maja Marolt Music
Journal:  Radiol Oncol       Date:  2016-07-19       Impact factor: 2.991

9.  Expression of miRNA and Occurrence of Distant Metastases in Patients with Hürthle Cell Carcinoma.

Authors:  Rok Petric; Barbara Gazic; Katja Goricar; Vita Dolzan; Radan Dzodic; Nikola Besic
Journal:  Int J Endocrinol       Date:  2016-07-28       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.